Legislation Quick Search
04/15/2021 11:45 PM
Pennsylvania House of Representatives
https://www.legis.state.pa.us/cfdocs/Legis/CSM/showMemoPublic.cfm?chamber=H&SPick=20170&cosponId=24359
Share:
Home / House Co-Sponsorship Memoranda

House Co-Sponsorship Memoranda

Subscribe to PaLegis Notifications
NEW!

Subscribe to receive notifications of new Co-Sponsorship Memos circulated

By Member | By Date | Keyword Search


House of Representatives
Session of 2017 - 2018 Regular Session

MEMORANDUM

Posted: August 2, 2017 03:37 PM
From: Representative Marty Flynn
To: All House members
Subject: Resolution Urging the FDA to Consider Lyme Disease Vaccinations
 
In the near future, I plan to introduce a resolution urging the United States Food and Drug Administration (FDA) to promptly consider candidates for Lyme disease vaccinations currently seeking approval under the drug approval process.

Lyme disease is the most commonly reported vector-borne illness in the United States, affecting 329,000 individuals each year. Pennsylvania, which is the leading state in reported cases of Lyme disease, had 7,400 cases in 2014 compared to 5,900 in 2013.

This disease not only threatens the quality of life of individuals, but also represents a significant economic burden. Over $1 billion in annual medical expenses in the United States have been attributed to Lyme disease as well as up to $10,000 per patient annually in lost productivity. In the Commonwealth, the cost in lost productivity may likely exceed $74 million.

Treatment options exist for individuals diagnosed with Lyme disease; however, there is currently no vaccination on the market despite one previously being available to consumers. Recent news has indicated that at least five groups of researchers at companies and academic centers are working on vaccinations for Lyme disease.

Given the impacts of Lyme disease on the Commonwealth and the United States, it is imperative that the FDA consider candidates for Lyme disease vaccinations. I hope you will join me in conveying the urgency of this issue. I appreciate your consideration and co-sponsorship.



Introduced as HR471